Peptide library / VIP

VIP

Vasoactive intestinal peptide is an endogenous 28-amino-acid neuropeptide. Aviptadil is a synthetic VIP preparation studied in specific formulations and routes.

Peptide & blend guide

The short version

Why people discuss it
Discussed for mold-associated/CIRS symptom protocols, including fatigue and brain fog; these community uses do not establish a general indication. Community interest does not establish benefit or a suitable treatment.
What it is
Vasoactive intestinal peptide is an endogenous 28-amino-acid neuropeptide. Aviptadil is a synthetic VIP preparation studied in specific formulations and routes.
Biggest caution
An endogenous signaling role does not establish broad immune support, and inhaled, intravenous and other synthetic preparations cannot share one evidence or dosing claim.
Stack context
Related profiles reflect adjacent community topics or biological context. They do not establish combination benefit, compatibility or a validated regimen.

Dose and frequency reference

Reference only — not a recommendation. Amounts describe source-specific community examples, selected study regimens or the named product label. They do not establish safety, effectiveness, product identity, or a suitable dose for any person. Never convert mg, mcg, or IU into syringe “units” without the exact product concentration.

Legacy community reference: no complete dosing regimen was independently corroborated by the two new source collections.

Intranasal

Community reference · Not clinical guidance
Amount
50 mcg per spray
Frequency
4 times daily
Duration / phase
1 month initial pattern

Published open-label and community protocol context; indication-specific The new inbox sources do not independently corroborate this complete regimen. Reference only; this does not establish safety, effectiveness or individual suitability.

Reference source · reviewed 2026-09-12
Evidence & sources · Community source profile

AxonRep synthesizes community discussion signals from its internal research corpus. Individual creator sources remain attributed to the synthesis; public reference sites used in the latest comparison are linked separately. The synthesis is not clinical evidence.

Back to the peptide library